Investigators conducted a network meta-analysis of phase 3 trials on MIBC treatments to provide comparative ranking of perioperative therapies.

Adjuvant nivolumab (Opdivo) continued to show benefits in disease-free survival (DFS) compared with placebo in patients with muscle-invasive urothelial carcinoma (MIUC) who underwent radical surgery, ...

Muscle-invasive bladder cancer patients who are ineligible or refuse cisplatin chemotherapy see “dramatic” improvements in ...

Event-free survival (EFS) improved by 60% and overall survival (OS) by 50% with the antibody-drug conjugate (ADC) enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) versus upfront radical ...

The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...

Petros Grivas, MD, PhD, discusses the overall survival and quality-of-life findings from the JAVELIN Bladder 100 trial of avelumab as maintenance therapy for advanced bladder cancer.

Designation places Mount Sinai among top one percent of cancer centers nationwide Mount Sinai Tisch Cancer Hospital Mount ...

Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma October 22, 2025 10:30 AM EDTCompany ...

An innovative new treatment option for bladder cancer, recently approved by the U.S. Food and Drug Administration, has been performed for the first time in Maryland.

The addition of durvalumab to bacillus Calmette-Guérin therapy significantly extended DFS for patients with high-risk non-muscle-invasive bladder cancer, according to results of a randomized phase 3 ...

On Sept. 5, 2025, the U.S. Food and Drug Administration (FDA) approved Inlexzo (gemcitabine intravesical system) for adults ...

FX-909, a first-in-class investigational oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma ...